

Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Announces Fourth Quarter and Full Year 2019 Financial Results

Apr 2 2020, 4:02 PM EDT

Kane Biotech Reschedules Release of Fourth Quarter and Full Year 2019 Financial Results and Associated Conference Call to April 2, 2020

Mar 25 2020, 4:57 PM EDT

Kane Biotech to Release Fourth Quarter and Full Year 2019 Financial Results on March 26 – Conference Call to Follow

Mar 20 2020, 8:00 AM EDT

Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	15.21m
Last Price	\$0.14
52-Week	\$0.075 - \$0.26

04/02/2020 11:58 AM EDT

Investor Relations

Edison Advisors
Joe Green
Senior Vice President, Investor Relations
1185 Avenue of the Americas
3rd Floor
New York, NY 10036
T: 646-653-7030
M: 917-575-7089
jgreen@edisongroup.com

Board of Directors

Mr. Philip Renaud

Chairman

Mr. Mark Nawacki

Director

Marc Edwards

Director, Interim Chief Executive Officer

Rashieda Gluck

Director

Kane Biotech Inc.

162-196 Innovation Drive
Winnipeg, Manitoba R3T 2N2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.